Clinical Trials Logo

Intestinal Diseases clinical trials

View clinical trials related to Intestinal Diseases.

Filter by:

NCT ID: NCT03698500 Recruiting - Ulcerative Colitis Clinical Trials

Specific microRNAs as Potential Biomarker for Inflammatory Bowel Disease

Start date: January 2017
Phase: N/A
Study type: Interventional

The aim of this study is to assess the ability of miR-320a and other specific microRNAs to follow the disease course in patients with Crohn`s disease (CD) and ulcerative colitis (UC), and to distinguish both entities, infectious colitis and healthy controls. Furthermore, the accuracy of miRNA-320a to distinguish CD or UC from irritable bowel syndrome (IBS) should be evaluated . The study is designed as a single center non-randomised prospective trial.

NCT ID: NCT03695783 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

The IBD&me Randomized Controlled Trial

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

Navigating the risk-benefit profiles of the various biologic options approved for inflammatory bowel disease (IBD) can be challenging for patients who are considering biologic therapies as a treatment option. Thus, there is a need for simple and efficient tools that elicit individual preferences and support the patient-provider interaction. The principal objective of this study is to assess the impact of an online decision aid called IBD&me on patient perceptions of shared-decision making as compared to a standardized education arm.

NCT ID: NCT03694223 Recruiting - Clinical trials for Irritable Bowel Syndrome

Health Education Delivery Methods for a Low Fermentable Carbohydrate Diet in Patients With Functional Bowel Disorders

Start date: January 3, 2016
Phase: N/A
Study type: Interventional

There is evidence for the use of a diet low in short chain fermentable carbohydrates (low FODMAP diet) in the management of functional gut symptoms, such as abdominal pain and bloating. However, the provision of advice on the low FODMAP diet can be challenging due to limited resources and the need for a dietitian with expertise in the low FODMAP diet. The aim of this study is to assess the feasibility in terms of recruitment and retention in planning a future trial. The purpose of the future trial will be to investigate the clinical and cost effectiveness, as well as the acceptability of different education methods of the low FODMAP diet for the treatment of IBS. To date, there are no studies on the implementation of the low FOMDAP diet using a mobile app or leaflets in the education of the low FODMAP diet. Therefore, a feasibility study design was chosen in order to obtain key data on recruitment and retention rates at each study group.

NCT ID: NCT03689257 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Study to Evaluate the Epidemiolog and the Charateristics "Omics" in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain

Start date: October 1, 2017
Study type: Observational

This is a prospective, observational, multicenter, population-based incidence cohort study which will enroll cases of IBD (CD, UC, or indeterminate colitis) diagnosed in adults over 18 months in Spain. In addition, each incident case that gave his/her informed consent, will be followed up for 12 months to determine changes in phenotype or disease location, the need for immunosuppressive and biologic treatments, and the need for hospital admissions and surgery during the first year after diagnosis. Also, samples of of blood, urine and stool will be collecte during the first year after diagnosis

NCT ID: NCT03675763 Completed - Clinical trials for Gastro-Intestinal Disorder

Efficacy of a Craniosacral Therapy Protocol in the Treatment of Infant Colic

Start date: March 2, 2015
Phase: N/A
Study type: Interventional

This is a randomised controlled trial that aims to determine the efficacy of craniosacral therapy for the treatment of infant colic. Manual therapy was applied to newborn infants diagnosed with colic who were distributed in an experimental and control group.

NCT ID: NCT03671980 Completed - Ulcerative Colitis Clinical Trials

IBD Self-management Website and Home Faecal Calprotectin Monitoring

Start date: April 4, 2017
Phase: N/A
Study type: Interventional

6 month exploratory feasibility study to assess if a combination of MyMedicalRecord supported self-management website and a home faecal calprotectin smartphone testing kit is a feasible and acceptable means for patients to monitor for signs of relapse after treatment de-escalation.

NCT ID: NCT03670693 Recruiting - Crohn Disease Clinical Trials

Non-invasive Approaches to Identify the Cause of Fatigue in Inflammatory Bowel Disease Patients.

IBD Fatigue
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

Crohn's disease (CD) presents with severe symptoms, but fatigue is a very predominant symptom that negatively impacts upon quality of life. Fatigue affects ~40% of patients when well and 80% of patients when the disease is active. It is the second commonest symptom that an IBD patient gets throughout their life-time. The IBD priority-setting partnership between the James Lind Alliance and the British Society of Gastroenterology has recently identified fatigue as an area of unmet clinical need and a priority research field, in which diagnosis and therapeutic intervention are lacking. Based on other diseases that present with fatigue, the cause of fatigue may be divided into peripheral fatigue, mainly driven by anomalies in muscle mass and function and central fatigue, mainly driven through decreased blood supply to the brain during exercise probably due to decreased heart and lung fitness. Research in IBD fatigue until now has been patchy with no convincing evidence that any treatment helps. There has been no research aimed at studying whole body function. It is imperative to have a better understanding of the alterations in muscle, brain, heart and lung function seen in these patients before specific treatments are researched. In this study, the investigators aim to recruit 32 CD patients, half with fatigue and half without. Subjects with active disease or with other known reasons of fatigue will be excluded. Findings in this group will be compared to 16 other healthy control volunteers of a similar age, gender and Body Mass Index. The study aims to recruit all participants over 36 months, and will target people aged from 16 to 60 years of age. Once recruited, the participants will be asked to provide their consent to take-part in 3 experiments on two separate days. These experiments have been designed to carefully consider potential fatigue burden, experimental practicality, and participant availability. Objective 1: The investigators aim to measure muscle fitness and strength by asking subjects to exercise using a stepper, whilst body mass and composition will be measured using an X-ray. This session will take 2 hours and be undertaken on one day. Objective 2: Peripheral fatigue: The investigators aim to non-invasively measure the recovery of muscle physiology after exercise by using magnetic resonance imaging after 5 min of exercise undertaken with a limb cuff. This will take ~1 hour. Objective 3: Central fatigue: while in the scanner and performing exercise, the investigators aim to non-invasively measure heart and brain blood flow before and after a few minutes of exercise using magnetic resonance imaging. This will take 2 hours. Experimental work for Objectives 2 and 3 will be undertaken on the same day. There will be ample time for recovery in between and during the different studies. There will be no further commitment from the participants required after these 2 study visits. IBD fatigue has never been studied in such detail. This unique work will allow identification of fatigue mechanisms, which can then be targeted with exercise, nutritional, or medical treatments.

NCT ID: NCT03667586 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Group Cognitive Behavioral Therapy for IBD Patients

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Inflammatory bowel disease (IBD) patients commonly suffer from disturbed psychosocial functioning and poor quality of life compared to other chronic disease patients. Clinicians are becoming growingly aware that addressing patients' psychological difficulties may improve disease management, however, there is not adequate evidence regarding the effect of psychotherapeutic interventions on psychosocial functioning and disease-related clinical and laboratory parameters. The aim of the present study is the evaluation of the effects of a targeted, cognitive behavioral psychotherapeutic intervention on symptom severity, levels of psychological distress and quality of life and inflammation and disease activity indices in IBD patients. An additional aim is the detection of psychological and biomedical parameters which may be associated with these effects.

NCT ID: NCT03653481 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Treating IBD With Inulin

Start date: October 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to see how the prebiotic inulin changes the gut bacteria (microbiome) of children and young adults with IBD and determine if this dietary intervention can help reduce disease activity.

NCT ID: NCT03648398 Not yet recruiting - Crohn's Disease Clinical Trials

Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

EDUMICILOR is a monocentric prospective pilot study for patients with inflammatory bowel disease (IBD). During the study, patients will participate in an online therapeutic education program. They will first have an appointment with a nurse to establish a personalized educational diagnosis. Then they will participate in the online therapeutic education program for about 6 months (depends on the educational needs, expectations and patient's availabilities). The main objective of this study is to assess the feasibility of an online therapeutic education program for IBD patients.